BridgeBio Pharma Inc (NAS:BBIO)
$ 27.94 0.18 (0.65%) Market Cap: 5.23 Bil Enterprise Value: 6.44 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 48/100

BridgeBio Pharma Inc at UBS Global Healthcare Virtual Conference Transcript

May 25, 2021 / 09:00PM GMT
Release Date Price: $57.68 (+1.26%)
Eliana Rachel Merle
UBS Investment Bank, Research Division - Analyst

I'm Ellie Merle. I'm one of the biotech analysts here at UBS. Thanks so much for joining us at the UBS Healthcare Conference. Very happy to have Neil Kumar, CEO and Founder of BridgeBio here with us today for a fireside chat. And with that, I'll turn it over to Neil.

Questions & Answers

Eliana Rachel Merle
UBS Investment Bank, Research Division - Analyst

Maybe taking a step back, can you sort of frame for us the business model and philosophy of BridgeBio's structure and how this could sort of increase R&D returns? And then kind of high-level, sort of what your key priorities are over the next couple of years?

Neil Kumar
BridgeBio Pharma, Inc. - Co-Founder, CEO & Director

Sure. Well, first of all, thanks so much for having me here. It's great to speak with you. Can you hear me okay, by the way, is it crystal clear to -- okay. Wonderful. So the BridgeBio business model is actually quite simple. It's something that we set up to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot